Response to “The Role of FcRn in the Pharmacokinetics of Biologics in Patients with Multiple Myeloma”
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.779
Abstract: To the Editor: Daratumumab, a therapeutic immunoglobulin G (IgG) 1j monoclonal antibody, targets CD38 for the treatment of multiple myeloma. In our article, we reported that daratumumab exhibited time-dependent and concentration-dependent pharmacokinetics (PK) consistent with… read more here.
Keywords: igg; response; multiple myeloma; igg patients ... See more keywords